stockrowSpyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.
- EPS
- −624.8%
- Free cash flow
- −108.8%
Quarter to September 2026, against a year earlier
Follow SYRE
Alert me
Spyre Therapeutics, Inc. (SYRE) EBITDA
Spyre Therapeutics, Inc.'s EBITDA for fiscal 2025 was −$209.6M, compared with −$208.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$250.2M. Over the past ten years it has ranged from −$241.3M (fiscal 2023) to −$11.2M (fiscal 2015); the current reading is higher than 18% of that period. Spyre Therapeutics, Inc. ranks 534th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$209.6M | — |
| FY2024 | −$208.6M | — |
| FY2023 | −$241.3M | — |
| FY2022 | −$83.1M | — |
| FY2021 | −$63.1M | — |
| FY2020 | −$80.4M | — |
| FY2019 | −$80.7M | — |
| FY2018 | −$45.8M | — |
| FY2017 | −$27.4M | — |
| FY2016 | −$21.7M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$105.7M | — |
| Jun 2026 | −$41.6M | — |
| Mar 2026 | −$45.6M | — |
| Dec 2025 | −$57.2M | — |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $234.3M |
| CAI Caris Life Sciences,�Inc. compare | $180.0M |
| TGTX TG Therapeutics, Inc. compare | $136.0M |
| PTGX Protagonist Therapeutics, Inc. compare | $56.4M |
| TWST Twist Bioscience Corporation compare | −$119.6M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$145.8M |
| IBRX ImmunityBio, Inc. compare | −$235.2M |
| SYRE Spyre Therapeutics, Inc. | −$250.2M |
| CYTK Cytokinetics, Incorporated compare | −$694.7M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on SYRE
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement